Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update
Muneeb Ahmed, Luigi Solbiati, Christopher L Brace, David J Breen, Matthew R Callstrom, J William Charboneau, Min-Hua Chen, Byung Ihn Choi, Thierry de Baère, Gerald D Dodd 3rd, Damian E Dupuy, Debra A Gervais, David Gianfelice, Alice R Gillams, Fred T Lee Jr, Edward Leen, Riccardo Lencioni, Peter J Littrup, Tito Livraghi, David S Lu, John P McGahan, Maria Franca Meloni, Boris Nikolic, Philippe L Pereira, Ping Liang, Hyunchul Rhim, Steven C Rose, Riad Salem, Constantinos T Sofocleous, Stephen B Solomon, Michael C Soulen, Masatoshi Tanaka, Thomas J Vogl, Bradford J Wood, S Nahum Goldberg, International Working Group on Image-Guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe, Muneeb Ahmed, Luigi Solbiati, Christopher L Brace, David J Breen, Matthew R Callstrom, J William Charboneau, Min-Hua Chen, Byung Ihn Choi, Thierry de Baère, Gerald D Dodd 3rd, Damian E Dupuy, Debra A Gervais, David Gianfelice, Alice R Gillams, Fred T Lee Jr, Edward Leen, Riccardo Lencioni, Peter J Littrup, Tito Livraghi, David S Lu, John P McGahan, Maria Franca Meloni, Boris Nikolic, Philippe L Pereira, Ping Liang, Hyunchul Rhim, Steven C Rose, Riad Salem, Constantinos T Sofocleous, Stephen B Solomon, Michael C Soulen, Masatoshi Tanaka, Thomas J Vogl, Bradford J Wood, S Nahum Goldberg, International Working Group on Image-Guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe
Abstract
Image-guided tumor ablation has become a well-established hallmark of local cancer therapy. The breadth of options available in this growing field increases the need for standardization of terminology and reporting criteria to facilitate effective communication of ideas and appropriate comparison among treatments that use different technologies, such as chemical (eg, ethanol or acetic acid) ablation, thermal therapies (eg, radiofrequency, laser, microwave, focused ultrasound, and cryoablation) and newer ablative modalities such as irreversible electroporation. This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies. An appropriate vehicle is proposed for reporting the various aspects of image-guided ablation therapy including classification of therapies, procedure terms, descriptors of imaging guidance, and terminology for imaging and pathologic findings. Methods are addressed for standardizing reporting of technique, follow-up, complications, and clinical results. As noted in the original document from 2003, adherence to the recommendations will improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes.
Conflict of interest statement
M.A. No relevant conflicts of interest to disclose. L.S. No relevant conflicts of interest to disclose. C.L.B. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received consultancy fees from NeuWave Medical, author and institution received payment for patents (planned, pending, or issued) from University of Wisconsin and NeuWave Medical, received payment for stock/stock options from NeuWave Medical. Other relationships: none to disclose. D.J.B. Financial activities related to the present article: paid for occasional proctoring by Galil Medical. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. M.R.C. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received grants from Galil Medical, Siemens Medical, GE Medical, Thermedical. Other relationships: none to disclose. J.W.C. No relevant conflicts of interest to disclose. M.H.C. No relevant conflicts of interest to disclose. B.I.C. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: institution received a research grant from Samsung Electronics. Other relationships: none to disclose. T.d.B. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received personal fees from Terumo, a grant from HS-Medical, and payment for travel to a meeting from Boston-Scientific. Other relationships: none to disclose. G.D.D. No relevant conflicts of interest to disclose. D.E.D. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: paid for board membership by BSD Medical, received consultancy fees from BSD Medical and Covidien, received grants or has grants pending from NeuWave Medical, received payment for lectures including service on speakers bureaus from BSD Medical, was paid royalties by Springer Verlag and UpToDate, received stock or stock options from BSD Medical. Other relationships: none to disclose. D.A.G. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received a research grant from Covidien/Valleylab. Other relationships: none to disclose. D.G. No relevant conflicts of interest to disclose. A.R.G. Financial activities related to the present article: received consulting fee or honorarium from Covidien, received fees for participatient in review activities such as data monitoring boards, statistical analysis, end point committees, and the like from Covidien. Financial activities not related to the present article: was paid for board membership, consultancy, and lectures including service on speakers bureaus by Covidien. Other relationships: none to disclose. F.T.L. Financial activities related to the present article: received payment from NeuWave Medical. Financial activities not related to the present article: received royalties from Covidien, is a stockholder and on the Board of Directors for NeuWave Medical, has a patent on the Switching Controller with royalties paid from Covidien, has multiple patents on heat-based thermal therapies for microwave ablation systems licensed to NeuWave Medical. Other relationships: none to disclose. E.L. No relevant conflicts of interest to disclose. R.L. No relevant conflicts of interest to disclose. P.J.L. No relevant conflicts of interest to disclose. T.L. No relevant conflicts of interest to disclose. D.S.L. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: institution received grants or has grants pending from Endocare and Ethicon Endo-Surgery, received payment for lectures including service on speakers bureaus from Philips. Other relationships: none to disclose. J.P.M. No relevant conflicts of interest to disclose. M.F.M. No relevant conflicts of interest to disclose. B.N. No relevant conflicts of interest to disclose. P.L.P. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: received a grant from Celon Olympus; fees for conferences from Siemens Medical Solutions; consultant’s honoraries from Terumo Europe, Terumo Germany, and Microsulis; materials from AngioDynamics. Other relationships: none to disclose. P.L. No relevant conflicts of interest to disclose. H.R. No relevant conflicts of interest to disclose. S.C.R. No relevant conflicts of interest to disclose. R.S. No relevant conflicts of interest to disclose. C.T.S. No relevant conflicts of interest to disclose. S.B.S. Financial activities related to the present article: institution received a grant from GE Healthcare; author received consulting fee or honorarium from AngioDyamics, Covidien, and GE Healthcare. Financial activities not related to the present article: none to disclose. Other relationships: none to disclose. M.C.S. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: author received consultancy fees from Guerbet LLC, BTG, Merit Medical; institution received grants or has grants pending from Guerbet LLC and BTG; author received payment for lectures including service on speakers bureaus from Sirtex; author received royalties from Cambridge University Press. Other relationships: none to disclose. M.T. No relevant conflicts of interest to disclose. T.J.V. No relevant conflicts of interest to disclose. B.J.W. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: institution received grants or has grants pending from Cooperative Research and Development Agreement (CRADA) Philips Healthcare, CRADA Biocompatibles BTG, CRADA Perfint, CRADA Celsion, CRADA Invivo; the National Institutes of Health has intellectual property in the field. Other relationships: none to disclose. S.N.G. Financial activities related to the present article: institution received a grant for sponsored research from AngioDynamics; author received consulting fee or honorarium from AngioDynamics. Financial activities not related to the present article: author received consultancy fees from Cosman Medical and institution received grants or has grants pending from Cosman Medical. Other relationships: none to disclose.
Copyright © 2014.
Source: PubMed